Giulia Cassone
Overview
Explore the profile of Giulia Cassone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maisonobe L, Korganow A, Berti A, Deroux A, Dupin N, Aractingi S, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39847537
Objectives: Urticarial vasculitis (UV) is characterized by atypical urticarial lesions and leukocytoclastic vasculitis, sometimes with extracutaneous manifestations. First-line treatment is based on colchicine, hydroxychloroquine, dapsone or low-dose glucocorticoids. In refractory...
2.
Sorin B, Papo M, Sinico R, Teixeira V, Venhoff N, Urban M, et al.
J Autoimmun
. 2024 Nov;
149:103338.
PMID: 39549485
Objectives: Current guidelines suggest treating poor-prognosis eosinophilic granulomatosis with polyangiitis (EGPA) with a combination of glucocorticoids (GCs) plus cyclophosphamide (CYC). However, there is little data to support the need for...
3.
Lubrano E, Lubrano E, Armuzzi A, Armuzzi A, Scriffignano S, Scriffignano S, et al.
Reumatismo
. 2024 Nov;
PMID: 39526478
Objective: To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD). Methods: An exhaustive literature search was...
4.
Manfredi A, Venerito V, Cazzato M, Sambataro G, Zanini U, Gozzi F, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518649
Progressive pulmonary fibrosis (PPF) has been associated with a worse prognosis, even when interstitial lung disease (ILD) is related to rheumatic diseases. Since many differences are detectable among rheumatic diseases...
5.
Muratore F, Marvisi C, Cassone G, Ricordi C, Boiardi L, Mancuso P, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39150490
Objectives: To assess the maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-GCA (LV-GCA). Methods: 17 patients with active LV-GCA were previously treated...
6.
Manfredi A, Sambataro G, Rai A, Cerri S, Sambataro D, Vacchi C, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39063962
Background: Interstitial lung disease (ILD) represents a frequent cause of morbidity and mortality in primary Sjogren syndrome (pSS). However, the prevalence and behavior of pSS-ILD remains incomplete, largely based on...
7.
Sebastiani M, Manfredi A, Croci S, Faverio P, Cassone G, Vacchi C, et al.
Expert Opin Investig Drugs
. 2024 Jul;
33(8):815-827.
PMID: 38967534
Introduction: Pulmonary involvement is one of the most common extra-articular manifestations of rheumatoid arthritis (RA), a systemic inflammatory disease characterized by joint swelling and tenderness. All lung compartments can be...
8.
Treppo E, Isola M, De Martino M, Padoan R, Giollo A, Urban M, et al.
Rheumatol Adv Pract
. 2024 Mar;
8(1):rkae001.
PMID: 38515585
Objectives: The primary objective of this study was the translation and validation of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire into Italian, denoted as AAV-PRO_ita. The secondary objective was to...
9.
Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
Sebastiani M, Venerito V, Laurino E, Gentileschi S, Atzeni F, Canofari C, et al.
J Clin Med
. 2023 Nov;
12(22).
PMID: 38002655
Background: The INBUILD study demonstrated the efficacy of nintedanib in the treatment of progressive fibrosing interstitial lung disease different to idiopathic pulmonary fibrosis, including rheumatoid arthritis (RA)-related ILD. Nevertheless, the...
10.
Muratore F, Marvisi C, Cassone G, Boiardi L, Mancuso P, Besutti G, et al.
Rheumatology (Oxford)
. 2023 May;
63(1):64-71.
PMID: 37195423
Objectives: To assess the impact of tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs) on clinical manifestations, and vessel inflammation and damage in large vessel-GCA (LV-GCA). Methods: In this prospective observational...